- Home
- Medical news & Guidelines
- Anesthesiology
- Cardiology and CTVS
- Critical Care
- Dentistry
- Dermatology
- Diabetes and Endocrinology
- ENT
- Gastroenterology
- Medicine
- Nephrology
- Neurology
- Obstretics-Gynaecology
- Oncology
- Ophthalmology
- Orthopaedics
- Pediatrics-Neonatology
- Psychiatry
- Pulmonology
- Radiology
- Surgery
- Urology
- Laboratory Medicine
- Diet
- Nursing
- Paramedical
- Physiotherapy
- Health news
- Fact Check
- Bone Health Fact Check
- Brain Health Fact Check
- Cancer Related Fact Check
- Child Care Fact Check
- Dental and oral health fact check
- Diabetes and metabolic health fact check
- Diet and Nutrition Fact Check
- Eye and ENT Care Fact Check
- Fitness fact check
- Gut health fact check
- Heart health fact check
- Kidney health fact check
- Medical education fact check
- Men's health fact check
- Respiratory fact check
- Skin and hair care fact check
- Vaccine and Immunization fact check
- Women's health fact check
- AYUSH
- State News
- Andaman and Nicobar Islands
- Andhra Pradesh
- Arunachal Pradesh
- Assam
- Bihar
- Chandigarh
- Chattisgarh
- Dadra and Nagar Haveli
- Daman and Diu
- Delhi
- Goa
- Gujarat
- Haryana
- Himachal Pradesh
- Jammu & Kashmir
- Jharkhand
- Karnataka
- Kerala
- Ladakh
- Lakshadweep
- Madhya Pradesh
- Maharashtra
- Manipur
- Meghalaya
- Mizoram
- Nagaland
- Odisha
- Puducherry
- Punjab
- Rajasthan
- Sikkim
- Tamil Nadu
- Telangana
- Tripura
- Uttar Pradesh
- Uttrakhand
- West Bengal
- Medical Education
- Industry
COVID: Optimus Pharma submits phase 3 trials interim result for Molnupiravir capsules
Optimus has approached DCGI to seek Emergency Use Authorization for Molnupiravir in India, the release said.
Hyderabad: Optimus Pharma on Wednesday said that it has submitted interim result of Phase III Clinical Trials for orally administered Molnupiravir capsules on patients with Mild Covid infection.
With acute shortage of antiviral drugs in the market against the SARS-CoV-2 infection, it is imperative that more drugs with potent antiviral activity against SARS-CoV-2 be introduced, the pharmaceutical company said in a release here.
Company Chairman and Managing Director Dr D Srinivasa Reddy said that Optimus pharma has internally developed the Active Pharmaceutical Ingredient (API) and the formulations for the product and had obtained approval for conducting Phase 3 Clinical Trial.
As per the clinical trial protocol approved, 1218 subjects with mild COVID-19 will be randomised in the study in a 1:1 ratio to Molnupiravir with standard of care or standard of care alone, he said.
The treatment duration is a maximum of five days and the total study duration will be maximum for 28 days from randomisation, Dr Reddy added.
"Optimus is all geared to immediately begin manufacturing of Molnupiravir capsules for COVID-19 patients in India.
The interim results on 353 patients have shown promising results of Molnupiravir.
The drug has been successful in reducing viral load effectively with RT-PCR negativity achieved 78.3 percent in test arm compared to 48.4% in standard of care arm on Day 5. Day 10 and Day 14 of the treatment duration has also given excellent results wherein remaining patients have successfully achieved RT-PCR negativity, the pharma company claimed.
The trial has also reveals clinical improvement in significantly high proportion of patient's health.
The safety of the drug has also been established with no observed side effects, co-morbidity or morbidity observed during and after the treatment duration," Dr Reddy said.
Optimus has approached the Drugs Controller General of India (DCGI) to seek Emergency Use Authorization for Molnupiravir in India, the release added.
optimus pharmaoptimus pharma newsmolnupiravir capsulesclinical trialdcgicovid-19coronaviruscovid drug
Source : UNIRuchika Sharma joined Medical Dialogue as an Correspondent for the Business Section in 2019. She covers all the updates in the Pharmaceutical field, Policy, Insurance, Business Healthcare, Medical News, Health News, Pharma News, Healthcare and Investment. She has completed her B.Com from Delhi University and then pursued postgraduation in M.Com. She can be contacted at editorial@medicaldialogues.in Contact no. 011-43720751
Next Story